Esomeprazole
- Generic Name
- Esomeprazole
- Brand Names
- Nexium, Vimovo, Nexium Control
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N3O3S
- CAS Number
- 119141-88-7
- Unique Ingredient Identifier
- N3PA6559FT
- Background
Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison ...
- Indication
Esomeprazole is indicated for the treatment of acid-reflux disorders including healing and maintenance of erosive esophagitis, and symptomatic gastroesophageal reflux disease (GERD), peptic ulcer disease, H. pylori eradication, prevention of gastrointestinal bleeds with NSAID use, and for the long-term treatment of pathological hypersecretory conditions incl...
- Associated Conditions
- Duodenal Ulcer, Erosive Esophagitis, Gastro-esophageal Reflux Disease (GERD), Heartburn, Helicobacter Pylori Infection, Stress Ulcers, Upper Gastrointestinal Hemorrhage, Zollinger-Ellison Syndrome, Acute benign gastric ulcers, Develop NSAID-induced gastric ulcers, Maintenance of healing Erosive esophagitis, Postendoscopy Bleeding
- Associated Therapies
- -
Validation of RDQ Questionnaire
- Conditions
- First Posted Date
- 2006-02-15
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 350
- Registration Number
- NCT00291746
- Locations
- 🇬🇧
Research Site, West Bromwich, United Kingdom
The Utility of Nexium in Chronic Cough and Reflux Disease
- First Posted Date
- 2006-02-06
- Last Posted Date
- 2012-01-10
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 40
- Registration Number
- NCT00287339
- Locations
- 🇺🇸
UNC Gastroenterology, UNC Pulmonology, UNC ENT, Chapel Hill, North Carolina, United States
Esomeprazole in PPI Failures - IMPROVE
- Conditions
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2009-03-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 450
- Registration Number
- NCT00272701
- Locations
- 🇸🇪
Research site, Balsta, Sweden
🇸🇪Research Site, Vasteras, Sweden
ASTERIX: Low Dose ASA and Nexium
- Conditions
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 960
- Registration Number
- NCT00251966
- Locations
- 🇬🇧
Research Site, Edinburgh, United Kingdom
A Study to Prevent Rebleeding After Initial Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer
- Conditions
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2011-06-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1312
- Registration Number
- NCT00251979
- Locations
- 🇬🇧
Research Site, Leeds, United Kingdom
Nexium Dyspepsia/AST
- Conditions
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1200
- Registration Number
- NCT00251992
- Locations
- 🇬🇧
Research Site, Watford, United Kingdom
Chest Pain Pilot Study
- Conditions
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 600
- Registration Number
- NCT00251901
- Locations
- 🇸🇪
Research Site, Östersund, Sweden
Esomeprazole (NEXIUM) vs. Surgery
- Conditions
- Interventions
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2012-08-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 626
- Registration Number
- NCT00251927
- Locations
- 🇬🇧
Research Site, Salford, United Kingdom
Nexium Dyspepsia/AST
- Conditions
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1500
- Registration Number
- NCT00251914
- Locations
- 🇨🇭
Research Site, St. Gallen, Switzerland
HEARD (Long Term) Study - Histology of the Esophagus in Acid-Related Disease
- Conditions
- First Posted Date
- 2005-10-25
- Last Posted Date
- 2009-03-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 350
- Registration Number
- NCT00243724
- Locations
- 🇨🇦
Research Site, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.